Photodynamic Therapy for Field Cancerization in the Skin: Where Do We Stand?

被引:2
|
作者
Bakirtzi, Katerina [1 ,2 ]
Papadimitriou, Ilias [1 ]
Vakirlis, Efstratios [1 ]
Lallas, Aimilios [1 ]
Sotiriou, Eleni [1 ]
机构
[1] Aristotle Univ Thessaloniki, Dept Dermatol & Venereol 1, Thessaloniki, Greece
[2] Aristotle Univ Thessaloniki, Delfon 124,POB 54643, Thessaloniki, Greece
来源
DERMATOLOGY PRACTICAL & CONCEPTUAL | 2023年 / 13卷 / 04期
关键词
actinic keratosis; photodynamic therapy; skin field cancerization; METHYL-AMINOLEVULINATE; ACTINIC KERATOSES; 5-AMINOLEVULINIC ACID; BF-200; ALA; TRANSPLANT RECIPIENTS; RANDOMIZED-TRIAL; DOUBLE-BLIND; PHASE-III; EFFICACY; FACE;
D O I
10.5826/dpc.1304a291
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Introduction: Photodynamic therapy (PDT) with a photosensitizer is available for the treatment of multiple actinic keratoses (AKs) in a restricted skin area or, as it is established, for the field-cancerized skin.Objectives: Our review aims to present the up-to-date literature on skin field cancerization using PDT employing different topical photosensitizers, modified light delivery protocols and combination treatments to obtain excellent efficacy and safety in everyday clinical practice.Methods: We sought PubMed, MEDLINE, Scopus, OVID, Embase, Science Direct, Cochrane Library, Research Gate and Google Scholar for [(aminolevulinic acid OR aminolevulinate) AND photodynamic therapy] with (field-directed OR field cancerization, (actinic keratosis), and (efficacy OR effectiveness OR pain OR tolerability) for studies published until February 2023.Results: Advantages of PDT compared to the other field treatments, including imiquimod, 5-fluorouracil, ingenol mebutate gel and diclofenac, reported better cosmetic outcomes and greater patient satisfaction. On the other hand, some drawbacks of field PDT include pain and treatment duration. Alternate illumination methods have also been investigated, including daylight as a light source. Pretreating the affected area may enhance photosensitizer absorption leading to better therapeutic results, while combinational treatments have also been tested. Patients prefer daylight PDT to traditional light sources since it is more well-tolerated and equally effective. Even as a preventive treatment, field PDT yields promising outcomes, especially for high-risk individuals, including organ transplant recipients.Conclusions: This review provides a thorough display of the field of PDT on cancerized skin, which will facilitate physicians in applying PDT more efficiently and intuitively.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Particle therapy in lung cancer: Where do we stand?
    Pijls-Johannesmata, Madelon
    Grutters, Janneke P. C.
    Lambin, Philippe
    De Ruysscher, Dirk
    CANCER TREATMENT REVIEWS, 2008, 34 (03) : 259 - 267
  • [32] Gene Therapy for Heart Failure: Where Do We Stand?
    Charbel Naim
    Armen Yerevanian
    Roger J. Hajjar
    Current Cardiology Reports, 2013, 15
  • [33] Photodynamic therapy: Where do we go from here?
    Moro-Sibilot, D
    Brambilla, C
    EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (03) : 399 - 400
  • [34] Consolidation therapy in ovarian cancer: Where do we stand?
    Dearnley, Daynelle D.
    McMeekin, D. Scott
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2006, 18 (01) : 3 - 7
  • [35] Intravenous bisphosphonate therapy for osteoporosis: where do we stand?
    Bone H.G.
    Schurr W.
    Current Osteoporosis Reports, 2004, 2 (1) : 24 - 30
  • [36] 30 YEARS OF PACEMAKER THERAPY - WHERE DO WE STAND
    STANGL, K
    WIRTZFELD, A
    ALT, E
    BLOMER, H
    ZEITSCHRIFT FUR KARDIOLOGIE, 1990, 79 (06): : 383 - 395
  • [37] Antihypertensive drug therapy. Where do we stand?
    Middeke, M.
    INTERNIST, 2015, 56 (03): : 230 - +
  • [38] Psychedelic Therapy with Psilocybin and Psychotherapy - Where do we Stand?
    Karow, Anne
    PSYCHOTHERAPIE PSYCHOSOMATIK MEDIZINISCHE PSYCHOLOGIE, 2023, 73 (03/04) : 99 - 100
  • [39] Gene therapy for thyroid cancer: Where do we stand?
    DeGroot, LJ
    Zhang, RS
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (07): : 2923 - 2928
  • [40] Endocrine therapy in ovarian cancer: where do we stand?
    Paleari, Laura
    DeCensi, Andrea
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2018, 30 (01) : 17 - 22